O’Brien Medical Announces First 5 ETF Test Sites
O’Brien Medical announces confirmation of the first five field testing sites for it’s premier product, the ETF128. These test centers were chosen for their excellent reputations, resident experts and high volume diabetic foot clinics. Feedback provided through anonymous surveys will inform final design improvements prior to anticipated product launch in 2014. Field testing is an essential milestone for the product on its path to commercialization and the company gratefully acknowledges those clinicians assisting us with this important task.